PRPH2

Photoreceptors are the cells in the retina that capture light, and each one has a stack of tightly packed membrane disks called the outer segment. Peripherin-2, the protein made by PRPH2, sits in the outer segments of both rod and cone photoreceptors and helps shape, stabilize, and compact these disks. Because the outer segments must be continually renewed, a faulty peripherin-2 protein can leave photoreceptors unable to maintain their structure, which over time can lead to their decline. In older reports, this gene may be referred to as RDS; it's simply a former name for the same gene. Peripherin-2 normally partners with a related protein called ROM1, and in rare situations disease can arise from the combined effect of a change in PRPH2 together with a change in ROM1, an unusual pattern known as digenic inheritance.

The way PRPH2-related disease affects vision depends heavily on which part of the retina is most involved. When the condition behaves like retinitis pigmentosa, the rod photoreceptors that support night and side vision tend to be affected first, causing difficulty seeing in dim light and a gradual narrowing of the visual field. When the disease centers on the macula, the central part of the retina used for reading and fine detail, people may instead notice changes in central vision, glare sensitivity, or distortion. In a study of two Italian siblings who carried the same PRPH2 variant, one developed a more cone-driven, macular pattern of disease while the other showed a more generalized rod problem, illustrating how varied the same change can be within one family. In a large study of 241 people from 168 families, the median age at which symptoms began was 40 years, and researchers described six distinct patterns on retinal imaging ranging from pattern and vitelliform dystrophies to central areolar choroidal dystrophy and retinitis pigmentosa. In that cohort, symptoms tended to begin earlier in people whose disease resembled retinitis pigmentosa than in those with a pseudo-Stargardt pattern dystrophy. Overall vision was often relatively preserved, with many patients retaining good central acuity, but outcomes varied widely by variant and disease type.

It is well established that PRPH2 is a common and important cause of inherited retinal disease. A systematic review reported that PRPH2-associated retinal disease accounts for about a quarter of pattern dystrophies and up to roughly 5% of inherited retinal dystrophies overall. In a five-year assessment of inherited retinal disorders across Scotland, PRPH2 (RDS) was among the most common causal genes identified. Researchers have also found some links between the type of variant and the likely disease pattern. In one case series, missense changes (single-letter swaps in the protein) in a region called the D2 loop tended to be associated with more severe cone-rod degeneration and poorer visual outcomes, while variants that reduce the amount of working protein were more often linked to pattern dystrophies and better retained vision. Most PRPH2 disease is passed on in an autosomal dominant (definition: An inheritance pattern where a single altered copy of a gene, from just one parent, is enough to cause the condition.) way, meaning a single altered copy of the gene can cause disease; in one Portuguese registry roughly 95% of PRPH2 cases were dominant. The role of peripherin-2 in maintaining photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) outer segments is also strongly supported, including by laboratory work in animal and cell models.

The biggest open question is why the same PRPH2 variant can produce very different disease in different people, even within one family. Because of this variability, knowing the exact variant does not allow a precise prediction of when symptoms will start or how quickly vision will change for any one person. The genotype (definition: A person's specific genetic makeup — which gene and which variant is causing their condition — as opposed to the phenotype, the symptoms it produces.)-to-phenotype (definition: The observable traits or symptoms a condition actually produces in a person — as opposed to the genotype, the underlying genetic cause.) patterns researchers have described are useful trends rather than firm rules, and authors have called for larger studies to clarify them. How the disease mechanism differs between rods and cones is still being worked out, and laboratory studies suggest the balance of harm from a toxic mutant protein versus simply having too little working protein may not be the same in the two cell types. The proportion of cases that are retinitis pigmentosa versus macular disease also appears to vary between populations. Therefore, the frequency of occurance by pattern type (due to a PRPH2 gene mutation) is not fixed worldwide.

The supplied evidence does not identify a treatment approved specifically for PRPH2-related retinal disease. Research into gene-directed approaches is ongoing but remains preclinical (definition: Research done in cells or animals, before a treatment is considered ready to be studied in people.), meaning it is still being studied in the laboratory rather than offered as care. Laboratory work using knock-in mouse models has suggested that because rods and cones respond differently to mutant peripherin-2, an effective therapy might need to combine reducing the harmful protein with supplying enough healthy protein — an insight meant to guide future treatment design. Separate studies in zebrafish have explored how peripherin-2 and its partner ROM1 contribute to building rod and cone outer segments, adding to the basic understanding of how the disease develops. These animal and cell findings are important for guiding research but are not themselves available treatments.

• How rods and cones differ in PRPH2 disease

  Preclinical laboratory research in mice.

  What was found:

  Rods were strongly affected by variants that interfere with the protein's ability to assemble properly, while cones tolerated the mutant protein better, suggesting a knockdown strategy might sustain cones longer.

  Why it matters:

  It helps explain why disease can look so different between people and points toward how future therapies might be designed.

  Limitation: Findings in mice do not always translate to humans and do not represent an available treatment.

• A large international picture of PRPH2 disease

  Observational human case series (retrospective).

  What was found:

  Symptoms typically began around age 40, and the retina showed six distinct imaging patterns, from pattern and vitelliform dystrophies to central areolar choroidal dystrophy and retinitis pigmentosa; the same imaging pattern could have different functional test results.

  Why it matters:

  It gives patients and clinicians a realistic sense of the range of PRPH2 disease and supports planning for future clinical trials.

  Limitation: Being retrospective and cross-site, it cannot precisely predict any individual's course.

• Systematic review of PRPH2 retinal disease features

  Systematic review.

  What was found:

  PRPH2 accounts for about 25% of pattern dystrophy and up to 5% of inherited retinal dystrophies, with clear phenotypic variability even among people carrying the same variant, and overlap with conditions like age-related macular degeneration and Stargardt disease.

  Why it matters:

  It underscores both how common and how variable PRPH2 disease is, and why genetic confirmation matters for diagnosis.

  Limitation: Reviews depend on the quality and consistency of the underlying studies and cannot establish cause on their own.

• Linking variant type to disease pattern

  Observational human case series.

  What was found:

  Missense variants in the D2 loop were more often associated with severe cone-rod degeneration and poor visual outcomes, while variants reducing working protein were more often linked to milder pattern dystrophies with better retained vision.

  Why it matters:

  It offers a general trend that may help set expectations, while highlighting that these are tendencies rather than certainties.

  Limitation: The number of patients is small, so the correlations need confirmation in larger groups.

• Same variant, different disease in two siblings

  Case report (two individuals).

  What was found:

  One sibling had more cone-driven, macular disease while the other had a more generalized rod problem, despite the identical variant.

  Why it matters:

  It is a clear, concrete illustration of why a PRPH2 result cannot fully predict how one person's vision will be affected.

  Limitation: A single family cannot represent the full range of PRPH2 disease.

Because most PRPH2 disease is autosomal dominant (definition: An inheritance pattern where a single altered copy of a gene, from just one parent, is enough to cause the condition.), a parent who carries a disease-causing variant has, on average, a one-in-two chance of passing it to each child, which is often relevant information for relatives. It's important for families to understand that carrying the same variant does not mean relatives will have the same severity, age of onset, or even the same type of vision problem. Therefore, one family member's experience may not predict another's. Beyond these points, the general guidance shown on every RP Hope gene page applies.

• Based on my imaging and electrophysiology results, which PRPH2 disease pattern best describes my case — for example a pattern dystrophy, central areolar choroidal dystrophy, or retinitis pigmentosa?
• What does my specific PRPH2 variant, and its inheritance pattern, mean for my central versus peripheral vision over time?
• Should ROM1 or other genes be checked to rule out a dual-gene contribution?
• How often should my retina be monitored, and with which tests?
• What do my results mean for my children or other blood relatives who might consider testing?
• Are there any registries or natural-history studies you would suggest I learn more about?

A confirmed genetic diagnosis is the foundation for understanding a PRPH2 result, and detailed retinal imaging and electrophysiology testing help define which pattern of disease is present. Because PRPH2 can occasionally act together with a change in the ROM1 gene, and because dual-gene findings can influence prognosis, comprehensive genetic testing and, where relevant, testing of family members can help clarify the picture. Learning more about what genetic testing involves and what to ask a genetic counselor can be a helpful starting point. Regular follow-up with a retinal specialist allows changes to be monitored over time and keeps you informed as research advances.